Surat Samachar

Coccidioidomycosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Coccidioidomycosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 17
16:44 2021
Coccidioidomycosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
” Coccidioidomycosis Pipeline Insights, 2021″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Coccidioidomycosis market. A detailed picture of the Coccidioidomycosis pipeline landscape is provided, which includes the disease overview and Coccidioidomycosis treatment guidelines.

DelveInsight’s “Coccidioidomycosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Coccidioidomycosis pipeline landscapes. 

The report comprises Coccidioidomycosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Coccidioidomycosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Coccidioidomycosis pipeline products.     

Coccidioidomycosis Overview

Coccidioidomycosis (also known as Valley Fever) is an infection usually caused by inhaling the spores (“seeds”) of either Coccidioides immitis or Coccidioides posadasii fungi. These spores are found in the soil in certain geographic areas (called endemic) and get into the air when the soil is disturbed. Coccidioidomycosis cannot be passed from person-to-person.

There are three forms of Coccidioidomycosis i.e. acute pulmonary coccidioidomycosis, chronic pulmonary coccidioidomycosis, and disseminated coccidioidomycosis. Disseminated coccidioidomycosis, is the most severe form of the disease and occurs in about 1% of all cases, usually in people who have a poor immune system or pregnant women. This form can spread to the nervous system, bones, joints or skin. 

Some of the key takeaways from the Coccidioidomycosis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Scynexis, Mycovia Pharmaceuticals, F2G, Amplyx Pharmaceuticals, etc., are developing therapies for the treatment of Coccidioidomycosis.

  • Emerging therapies such as Ibrexafungerp, VT-1598, Fosmanogepix, Olorofim, are expected to have a significant impact on the  Coccidioidomycosis market in the coming years.

Get an overview of pipeline landscape @ Coccidioidomycosis Clinical Trials Analysis 

Coccidioidomycosis Pipeline Therapies along with Key Players:

  • Ibrexafungerp: Scynexis

  • VT-1598: Mycovia Pharmaceuticals

  • Fosmanogepix: Amplyx Pharmaceuticals

  • Olorofim: F2G

Scope of Coccidioidomycosis Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Scynexis, Mycovia Pharmaceuticals, F2G, Amplyx Pharmaceuticals,and others.

  • Pipeline Therapies: Ibrexafungerp, VT-1598, Fosmanogepix, Olorofim, and others.

Table of Contents

1

Coccidioidomycosis Report Introduction

2

Coccidioidomycosis Executive Summary

3

Coccidioidomycosis Overview

4

Coccidioidomycosis- Analytical Perspective In-depth Commercial Assessment

5

Coccidioidomycosis Pipeline Therapeutics

6

Coccidioidomycosis Late Stage Products (Phase II/III)

7

Coccidioidomycosis Mid Stage Products (Phase II)

8

Coccidioidomycosis Early Stage Products (Phase I)

9

Coccidioidomycosis Preclinical Stage Products

10

Coccidioidomycosis Therapeutics Assessment

11

Coccidioidomycosis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Coccidioidomycosis Key Companies

14

Coccidioidomycosis Key Products

15

Coccidioidomycosis Unmet Needs

16 

Coccidioidomycosis Market Drivers and Barriers

17

Coccidioidomycosis Future Perspectives and Conclusion

18